Equity Research, Broker Reports, and media content on ABLYNX NV

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about ABLYNX NV
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on ABLYNX NV. We currently have 0 research reports from 0 professional analysts.

Open
12.6
Volume
0.4m
Range
12.4/12.6
Market Cap
761,007,835m
52 Week
8.20/14.7
Date Source Announcement
06Mar17 06:00 GNW ABLYNX'S PARTNER, MERCK KGaA, HAS PRESENTED NEW DATA FROM A PHASE Ib PSORIASIS STUDY OF THE BI-SPECIFIC ANTI-IL-17A/F NANOBODY AT THE ANNUAL AAD CONFERENCE
23Feb17 06:00 GNW ABLYNX ANNOUNCES 2016 FULL YEAR RESULTS
16Feb17 06:00 GNW ABLYNX WILL ANNOUNCE ITS 2016 FULL YEAR RESULTS WITH WEBCAST ON 23 FEBRUARY 2017
09Feb17 06:00 GNW ABLYNX TO PRESENT ADDITIONAL DATA FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, A POTENTIAL BEST-IN-CLASS TREATMENT FOR RHEUMATOID ARTHRITIS
06Feb17 06:00 GNW ABLYNX SUBMITS A MARKETING AUTHORISATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR CAPLACIZUMAB, ITS ANTI-vWF NANOBODY, FOR THE TREATMENT OF aTTP
26Jan17 06:00 GNW ABLYNX'S PARTNER, MERCK KGaA, REPORTS ENCOURAGING RESULTS WITH THE BI-SPECIFIC NANOBODY ANTI-IL-17A/F (M1095) IN A PHASE Ib CLINICAL STUDY IN PATIENTS WITH PSORIASIS
24Jan17 06:00 GNW VAN HERK INVESTMENTS B.V. ANNOUNCES 10.07% SHAREHOLDING IN ABLYNX
  • Frequency of research reports

     

  • Research reports on

    ABLYNX NV

  • Providers covering

    ABLYNX NV